BIONATURIS

Trading sesion


20/01/2017 Close

2.8400

Last price


14.46 mill. €

Capitalisation

-0.70

Dif.(%)


-8.68

% Year 2017

Last Trade

Last

2.8400

Ref.

2.8600

Dif.(%)

-0.70

Volume (Shares)

1,475

Turnover (€x1000)

4.20

Security

Security name

BIONATURIS (BIOORGANIC RESEARCH SERV.)

Ticker

BNT

ISIN

ES0184980003

NIF

A-11811163

Capital Admitted

254.508,95 Euros

Shares Admitted

5.090.179

Nominal

0,05 Euros

Trading

Continuo

Liquidity Provider

GVC GAESCO BEKA, S.V., S.A.

Registered Advisor

DCM ASESORES Dirección y Consultoría de Mercados, S.L.

Auditor

PAEZ & SERRANO AUDITORIES, S.L.U.

Address

AV DESARROLLO TECNOLOGICO 11, JEREZ DE LA FRONTERA

Contact

ir@bionaturis.com

Historical Summary

 20132014201520162017 until 20/01

Capital Admitted (thousands of euros)

210232232255255

Shares (x 1,000)

4,1924,6334,6335,0905,090

Period Close Price (euros)

4.75007.90003.60003.11002.8400

Period Last Price (euros)

4.75007.90003.60003.11002.8400

Period High Price (euros)

5.800013.98008.20005.23003.1500

Period Low Price (euros)

1.58003.53003.59002.65002.8400

Capitalisation (thousands of euros)

19,91136,60116,67915,83014,456

Volume (thousands of shares)

3103,3952,13642626

Turnover (thousands of euros)

1,06824,84911,9571,60876

Company Profile

Bionaturis -established in Cadiz in 2005- is a biopharmaceutical company developing and producing biomedical products for the pharmaceutical and veterinarian sectors. Bionaturis specializes in the prevention and treatment of niche diseases, such as orphan diseases.

As value proposition Bionaturis has chosen Nature as an optimized source for the production of biopharmaceuticals, substituting the traditional industrial cumbersome steel reactors for single use, disposable and naturally occurring individual reactors: FLYLIFEÒ.  FLYLIFEÒ makes use of natural resources to achieve and indeed surpass the productive capacity of traditional industry standards but utilizing up to ten-fold less space and fifteen-fold less investment.  Amongst others, in niche markets where currently there is no solution, these competitive advantages provide a profitable solution and gives renewed hope to millions of worldwide patients. 

Its mission is to position itself as leader within the field of new platforms for production of biopharmaceuticals for veterinary and human use, and convert itself into a worldwide reference entity for the development of orphan drugs.

To complete its mission Bionaturis has chosen a mixed business model which combines short-term income through R+D services and production for third parties (BNT-CDMO), this in combination with co-development of biopharmaceuticals, which generates incomes through licensing royalties and the completion of milestones in the medium and long term (BNT-PRODUCTS).

 Year on year Bionaturis has increased the portfolio of international patents, either developed internally or acquired through license.  

Relevant Facts and Notices

Financial Reports

Photo Gallery

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.

Copyright © Bolsas y Mercados Españoles 2017. All rights reserved. Disclaimer // Legal Disclaimer // Suppliers payment period